诱导多能干细胞
体细胞
疾病
再生医学
药物开发
表型
生物
人诱导多能干细胞
干细胞
药物发现
重编程
心脏病
药品
计算生物学
生物信息学
医学
遗传学
胚胎干细胞
药理学
基因
病理
作者
Shu Nakao,Dai Ihara,Koji Hasegawa,Teruhisa Kawamura
出处
期刊:European Cardiology Review
日期:2020-02-26
卷期号:15
被引量:6
摘要
Induced pluripotent stem cells (iPSCs) are derived from reprogrammed somatic cells by the introduction of defined transcription factors. They are characterised by a capacity for self-renewal and pluripotency. Human (h)iPSCs are expected to be used extensively for disease modelling, drug screening and regenerative medicine. Obtaining cardiac tissue from patients with mutations for genetic studies and functional analyses is a highly invasive procedure. In contrast, disease-specific hiPSCs are derived from the somatic cells of patients with specific genetic mutations responsible for disease phenotypes. These disease-specific hiPSCs are a better tool for studies of the pathophysiology and cellular responses to therapeutic agents. This article focuses on the current understanding, limitations and future direction of disease-specific hiPSC-derived cardiomyocytes for further applications.
科研通智能强力驱动
Strongly Powered by AbleSci AI